Objectives: The primary efficacy end point was the skin quality assessed by Visia on both groups at 12 weeks.
The second efficacy end point was the wrinkles reduction and the lifting effect assessed by the panel of two doctors and by patients from standardized digital photographs according to the SSAl and PSAl.
Validate the my personal technique of treatment of lateral and lower lid wrinkles with platelet rich plasma (Prp)
Introduction: Lateral (Crown’s feet) and lower lid wrinkles are among the first visible sign of skin ageing. Platelet rich plasma (Prp) has proved to be effective and safe on tissue regeneration in dermatology and reconstructive surgery. Despite this, guidelines on clinical indications and some technical aspects such its use (topical, intradermal, subdermal) or its frequency of treatments are lacking.
The goal of our prospective randomized study was to assess the efficacy of the topical Prp on reducing superficial eye wrinkles (lifting effect) and restoring the dermal matrix.
Materials / method: 50 women with moderate to severe periorbital wrinkles on a four-points facial wrinkles scale (FWS) were enrolled on the study. Patients were previously treated on the periorbital region by a single session of fractional CO2 laser and randomized in two homogeneous groups: 25 (group 1) applied 5 drops of topical Prp stored inside the poloxamer formulation twice a day for 12 weeks, and 25 (group 2) applied gentamicin and betamethasone twice a day for the first week and then hyaluronic acid gel for the following 11 weeks.
Results: Group 1: texture (5.8% Vs 14,3%; p<0.001), wrinkles (38% Vs 64%; p<0.001), pores (32,6% Vs 46,2%; p<0.001), PSAl (3.88 Vs 8.2, p <0.001) and SSAl (2.88 Vs 6.; p <0.001) improved significantly.
Group 2: texture (5.3% Vs 6,2%; p:NS), wrinkles (42% Vs 54%; p:NS), pores (34,2% Vs 49,6%; p:NS), PSAl (4,2 Vs 6,2 p:NS) and SSAl (3,1 Vs 5,6 p:NS) improved but failed to reach significative difference.
Conclusion: Our prospective study proves that Prp reduces superficial periorbital wrinkles and restore dermal matrix when used topically for a period of at least 12 weeks.
Declaraciones
¿Ha recibido algún tipo de financiamiento para realizar su investigación sobre esta temática?
No
¿Ha recibido algún pago, honorario u otra compensación por su trabajo acerca de esta investigación?
No
¿Tiene vínculos financieros con alguna entidad que podría llegar a competir estrechamente con los medicamentos, materiales o instrumentos tratados en su investigación?
No
¿Posee o ha solicitado una patente relacionada a los materiales, productos o instrumentos utilizados en su investigación?
No
Este trabajo no cuenta con el apoyo de ningún financiamiento directo o indirecto. El autor asume plena responsabilidad sobre el mismo.